An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan

Wu, Wei‐Chi; Kuo, Hsi-Kung; Yeh, Po-Ting; Yang, Chung–May; Lai, Chi-Chun; Chen, San-Ni

doi:10.1016/j.ajo.2012.06.010

Cited by 117 publications

(78 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recurrence of ROP after ranibizumab injection occurred at 7.3±3.5 weeks over 21 weeks of observation. With regard to bevacizumab, the early recurrence interval was reported to be 7.6±9.4 weeks [28]. With regard to the IOP, we did not find significant change at the first follow-up after intravitreal injection of 0.25 mg ranibizumab.…”

Section: Discussioncontrasting

confidence: 66%

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Zhou

Jiang

Bai

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 66%

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Zhou

Jiang

Bai

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In addition, ROP management with diode laser and antivascular endothelial growth factor agents, may contribute to the decrease in blindness due to ROP; this decrease is in accordance with reports in the developed world and may reflect improvement in screening and treating protocols. [41][42][43][44][45] This study has several limitations. Although based on a national registry data, a selection bias due to an underreporting of the blind children is possible due to the fact that registration is not legally required in Israel.…”

Section: Discussionmentioning

confidence: 99%

Trends in the incidence and causes of severe visual impairment and blindness in children from Israel

Mezer

Chetrit

Kalter‐Leibovici

et al. 2015

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

“…In recent years, a number of studies have reported promising re sults with anti-vascular endothelial growth factor (VEGF) inhibitors, particularly bevacizumab, for the treatment of APROP (6)(7)(8)(9) . Lesser refractive errors have been demonstrated following intravitreal beva cizumab (IVB) therapy compared to laser treatment (10)(11)(12)(13) .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Günay¹,

Çelik²,

Günay³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Approved by the following research ethics committee: Zeynep Kamil Maternity and Children's Disease Training and Research Hospital. ABSTRACTPurpose: To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP). Methods: Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations. Results: Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively). Conclusions:The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.

show abstract

An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan

Cited by 117 publications

References 60 publications

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Trends in the incidence and causes of severe visual impairment and blindness in children from Israel

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Contact Info

Product

Resources

About